(19)
(11) EP 3 705 153 B8

(12) CORRECTED EUROPEAN PATENT SPECIFICATION
Note: Bibliography reflects the latest situation

(15) Correction information:
Corrected version no 1 (W1 B1)

(48) Corrigendum issued on:
27.11.2024 Bulletin 2024/48

(45) Mention of the grant of the patent:
23.10.2024 Bulletin 2024/43

(21) Application number: 19161019.5

(22) Date of filing: 06.03.2019
(51) International Patent Classification (IPC): 
A61M 25/00(2006.01)
(52) Cooperative Patent Classification (CPC):
A61M 25/0014; A61M 25/0097

(54)

INJECTION MOLDED CANNULA SYSTEM

SPRITZGEGOSSENES KANÜLENSYSTEM

SYSTÈME DE CANULE MOULÉ PAR INJECTION

(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

(43) Date of publication of application:
09.09.2020 Bulletin 2020/37

(73) Proprietors:
  • Roche Diabetes Care GmbH
    68305 Mannheim (DE)
    Designated Contracting States:
    AT BE BG DE DK EE FI FR IT LT LU LV MT NL PT RO SE SI 
  • F. Hoffmann-La Roche AG
    4070 Basel (CH)
    Designated Contracting States:
    AL CH CY CZ ES GB GR HR HU IE IS LI MC MK NO PL RS SK SM TR 

(72) Inventors:
  • FREITAG, Christian
    68305 Mannheim (DE)
  • RASMUSSEN, Mads
    68305 Mannheim (DE)

(74) Representative: Rentsch Partner AG 
Kirchenweg 8 Postfach
8034 Zürich
8034 Zürich (CH)


(56) References cited: : 
WO-A2-99/21605
US-A- 4 430 081
 DE-C1- 3 530 349
US-A- 4 781 703
   
       
    Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).